SCHEMBL3659482

SCHEMBL3659482

CC(C)(C(=O)Nc1nc(-c2ccc(F)cc2)cs1)S(=O)(=O)N1CCC1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 10/20 0.52
LMNA P02545 10/20 0.52
MEN1 O00255 9/20 0.52
MAPK1 P28482 7/20 0.52
ALDH1A1 P00352 6/20 0.52
KDM4E B2RXH2 6/20 0.52
MAPT P10636 6/20 0.52
HPGD P15428 5/20 0.52
SMN1; SMN2 Q16637 2/20 0.52
KCNQ1 P51787 1/20 0.49
POLB P06746 1/20 0.49
PPARG P37231 2/20 0.48
NCOA2 Q15596 2/20 0.48
NCOA1 Q15788 2/20 0.48
NCOA3 Q9Y6Q9 2/20 0.48
GAA P10253 1/20 0.48
HTT P42858 3/20 0.47
USP2 O75604 2/20 0.47
HSD17B10 Q99714 2/20 0.47
MMP2 P08253 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3661597 0.90 ABL1 (0.56) KMT2ALMNAMEN1MAPK1ALDH1A1
SCHEMBL3662329 0.89 ROCK1 (0.50) KMT2ALMNAMEN1MAPK1ALDH1A1
SCHEMBL3658990 0.84 LMNA (0.53) KMT2ALMNAMEN1ALDH1A1KDM4E
SCHEMBL3655183 0.81 LMNA (0.59) KMT2ALMNAMEN1MAPK1ALDH1A1
SCHEMBL3659111 0.80 NPC1 (0.59) KMT2ALMNAMEN1MAPK1ALDH1A1
SCHEMBL3656851 0.80 ALDH1A1 (0.55) KMT2ALMNAMEN1MAPK1ALDH1A1
SCHEMBL3178473 0.79 KMT2A (0.62) KMT2ALMNAMEN1MAPK1ALDH1A1
SCHEMBL13015623 0.79 KMT2A (0.62) KMT2ALMNAMEN1MAPK1ALDH1A1
SCHEMBL3655670 0.79 ATAD2 (0.43) KMT2ALMNAMEN1MAPK1ALDH1A1
SCHEMBL3659515 0.79 ATAD2 (0.53) KMT2ALMNAMEN1MAPK1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8546563-B2 Compounds which modulate the CB2 receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-10-01 US claimed
EP-2217565-B1 COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR BOEHRINGER INGELHEIM INT (DE) 2013-05-22 EP claimed
US-20100331304-A1 Compounds Which Modulate The CB2 Receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-12-30 US claimed
EP-2217565-A1 COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR Boehringer Ingelheim International GmbH (DE) 2010-08-18 EP claimed
WO-2009061652-A1 COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-05-14 WO claimed
US-8546563-B2 Compounds which modulate the CB2 receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-10-01 US disclosed
US-8546563-B2 Compounds which modulate the CB2 receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-10-01 US disclosed
US-8546563-B2 Compounds which modulate the CB2 receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-10-01 US disclosed
EP-2217565-B1 COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR BOEHRINGER INGELHEIM INT (DE) 2013-05-22 EP disclosed
US-20100331304-A1 Compounds Which Modulate The CB2 Receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-12-30 US disclosed
US-20100331304-A1 Compounds Which Modulate The CB2 Receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-12-30 US disclosed
US-20100331304-A1 Compounds Which Modulate The CB2 Receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-12-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100331304-A1 Compounds Which Modulate The CB2 Receptor CNR2, CNR1, OPRL1 KMT2A 3644/4885LMNA 4481/4885MEN1 4834/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.